Mercy BioAnalytics

Waltham, MA · Founded 2018 · Privately Held (backing)

Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer. Mercy BioAnalytics is based in Waltham, MA and was founded in 2018. It was valued at $122 million at its later-stage round in Mar 2023, the last priced event on record. It has raised $127 million across 1 recorded round; the latest was a $27.3 million early-stage round in Nov 2020.

PMV mark · valuation
$122.0M
Oct 2026
Priced at
its later-stage round
Mar 2023
Total raised
$127.3M
Last round
Early Stage VC
Nov 2020
What is Mercy BioAnalytics worth?
$122.0MPrivateMarketView mark · Oct 2026

Valued at $122.0M at its later-stage round, Mar 2023. Nothing has traded since.

Free account
More of Mercy BioAnalytics with a free account
  • ·The complete investor list: 25 names
  • ·Watch Mercy BioAnalytics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Mercy BioAnalytics funding history

1 rounds
DateRoundRaisedPost-money
Nov 2020Early Stage VC$27.3M▮
Unlock post-money valuations

Membership and data by Private Market View

Mercy BioAnalytics valuation

Mercy BioAnalytics was valued at $122 million at its later-stage round in Mar 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Mercy BioAnalytics raised?

Mercy BioAnalytics has raised $127 million in total; 1 of its rounds is on record. The largest on record was a $27.3 million early-stage round in Nov 2020.

Mercy BioAnalytics has filed 1 Form D with the SEC, most recently in Feb 2021 ($27.3 million sold to 57 investors).

How Mercy BioAnalytics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Mercy BioAnalytics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Mercy BioAnalytics

What is Mercy BioAnalytics worth?
Mercy BioAnalytics is valued at $122.0M as of Oct 2026. Valued at $122.0M at its later-stage round, Mar 2023. Nothing has traded since.
How much has Mercy BioAnalytics raised?
Mercy BioAnalytics has raised $127.3M in total funding across 1 recorded rounds.
When did Mercy BioAnalytics last raise?
Mercy BioAnalytics last raised in Nov 2020 (Early Stage VC), raising $27.3M.